What is Synchron?
Synchron is at the forefront of developing bloodstream-enabled solutions for previously untreatable nervous system conditions, positioning itself as a leader in interventional neuromodulation. The company is renowned for its Stentrode, a brain-computer interface currently in clinical trials. This groundbreaking technology aims to empower paralyzed patients to regain functional independence. Beyond motor neuroprosthetics, Synchron is also exploring endovascular neuromodulation for potential treatments of Parkinson's disease, epilepsy, depression, and hypertension. The company's technological foundation was established through a spin-out from the University of Melbourne, with initial development supported by grants from the U.S. Defense Advanced Research Projects Agency (DARPA) and the U.S. Department of Defense (DoD). The technology received public endorsement from former President Barack Obama, underscoring its potential to significantly improve the lives of individuals with disabilities.
How much funding has Synchron raised?
Synchron has raised a total of $50M across 2 funding rounds:
Series A
$10M
Series B
$40M
Series A (2017): $10M with participation from Defense Advanced Research Projects Agency and U.S. Department of Defense
Series B (2021): $40M led by Shanda Group, General Advance, Forepont Capital Partners, Khosla Ventures Acquisition, and ID8 Investments
Key Investors in Synchron
Shanda Group
Shanda Group is a global investment group with a strong focus on leading-edge technology and healthcare, likely providing strategic capital and market insights to Synchron's growth.
Forepont Capital Partners
Forepont Capital Partners, specializing in healthcare and life sciences, invests in biotech and medtech startups, offering scientific, technological, and financial support to advance innovative medical research.
Khosla Ventures Acquisition
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, with a broad investment focus including health and AI.
What's next for Synchron?
The substantial enterprise-level funding and recent strategic investment indicate Synchron is poised for significant scaling and advancement of its neurovascular bioelectronics platform. With its Stentrode technology progressing through clinical trials and potential applications targeting a range of debilitating neurological disorders, the company is well-positioned to further its mission. Future capital injections will likely fuel expanded clinical research, regulatory approvals, and the commercialization of its innovative solutions, potentially transforming patient care in neurology and beyond. The company's focus on interventional neuromodulation suggests a strategic expansion into new therapeutic areas, leveraging its core technology for broader impact.
See full Synchron company page
